Working… Menu

Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02588170
Recruitment Status : Active, not recruiting
First Posted : October 27, 2015
Last Update Posted : April 15, 2021
Information provided by (Responsible Party):
Hutchison Medipharma Limited